Therefore, to validate the effect of the proteasome system on the HIF‐1α expression level in CRC cells, we treated HT29 and LoVo cells separately for a period of time with specific concentrations of MG132 (Selleck, USA), a proteasome inhibitor. The gene discussed is HIF1A; the disease is colorectal carcinoma.